Patenting Biotechnology in Japan and recent hot issues

Slides:



Advertisements
Similar presentations
Unity of Invention Biotechnology Practice Julie Burke USPTO TC1600 Special Program Examiner.
Advertisements

The Intellectual Property Rights Regime in India & US: The Evolving Landscape February 15, 2014, The Hyatt Regency Hotel, New Delhi D. CALAB GABRIEL.
 1 IP High Court Case Review Finding of Invention Disclosed in Cited Prior Art in Finding Non-Inventive Step Pre-Meeting AIPLA Mid-Winter Meeting January.
Enablement Issues in the Examination of Antibodies
Written Description: Antibodies Bennett Celsa TC 1600 QAS
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703)
Industrial Property the Patent system
Selected Cases on Patents and Biotechnology WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
Antibody Patents in India Pravin Anand 14 th October 2011 Anand and Anand.
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Intellectual Property March 4, 2015 Don Keach Director, Intellectual Property Development and Technology Transfer Office Copyright University of Kentucky.
P A T E N T A T T O R N E Y S The EPO‘s approach in assessing inventive step for antibody claims Dr. Andreas Hübel M I C H A L S K I H Ü T T E R M A N.
JPO’s Reliance on Experimental Results in Patent Applications -From the Aspect of Requirements for Description of Claims and Specification- JPAA International.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
1 The Practice of Granting SUPPLEMENTARY PROTECTION CERTIFICATES in the German Patent and Trademark Office (GPTO) Andrea Münzberg Chemical Patent Division.
By Claire Baldock © Boult Wade Tennant 2011 Therapeutic Antibodies – Technical Introduction AIPPI Forum Hyderabad Pharma Workshop.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
Costa Rica Pharma and Biotech Patent Update AIPLA Spring Meeting Seattle, Washington May 2013 Costa Rica Luis Diego Castro Castro.
The Life Sciences Lawyer’s Guide to PTA and PTE
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Patenting Antibodies in Europe
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Korean Patent System and Recent Changes. Practices in Chemistry. Bong Sig SONG Korean Patent Attorney Y. S. CHANG & ASSOCIATES February 9 th 2008.
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
By Claire Baldock © Boult Wade Tennant 2011 Securing patent protection for therapeutic antibodies in Europe AIPPI Forum Hyderabad.
1 LAW DIVISION PATENT DIVISION TRADEMARK & DESIGN DIVISION ACCOUNTING & AUDITING DIVISION YUASA AND HARA LAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING.
Patenting Biotechnology in Japan and recent hot issues AIPLA Mid-Winter Meeting January 25, 2012 Ayako Kobayashi TMI Associates.
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
© 2011 Dannemann Siemsen. Todos os direitos reservados. Biotech IP issues in Brazil Gustavo Morais May 2011 Gustavo Morais May 2011.
New Practice of Unity of Invention (Article 37) "Unity of Invention" and "Shift Amendments" under the Revised Examination Guidelines in Japan JPAA International.
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Stem Cells from Skin Cells?!? The story of four little genes and a HUGE cellular change.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
Intellectual Property Rights and Pharmaceutical Industry
Patent Protection of Biotechnological Inventions in China Gesheng Huang Partner Zhongzi Law Office AIPLA Spring Meeting, May 12-14, 2011, San Francisco,
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Enablement requirement in view of recent IP court decisions Toshihiko Aikawa Japan Patent Attorneys Association International Activities Center AIPLA Mid-Winter.
Supreme Court Decision: Product-by-Process Claims AIPLA Annual Meeting 2015 IP Practice in Japan Pre-Meeting Seminar Yoshiki KITANO Japan Patent Attorneys.
Recent Supreme Court Decisions on Product-by-Process Claim (The Supreme Court Decisions on June 5, 2015) AIPLA Mid-Winter Institute January 26-27, 2016.
JP Supreme Court (Nov. 17, 2015) Patent Term Extension based on a Second Marketing Approval Pre-Meeting AIPLA MWI La Quinta, CA: Jan.26, 2016 Hirokazu.
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
Recent Developments in Pharma Patent Case Laws in Japan at GPIP Takanori ABE Attorney at Law (JP&NY) Guest Professor, Osaka University Graduate.
Janeway’s Immunobiology
Nov. 26, 2006 Kuzuwa & Partners1 Care required to draft pharma patents and prosecution of pharma patents Ahmedabad, November 26, 2006 Kiyoshi Kuzuwa Patent.
Basse Asplund, M Sc, Ph D Patent Attorney and Partner Stockholm, Uppsala, Göteborg och Lund.
Antibody Decisions and Their Compliance with the Written Description Requirement Workgroup
The Life Sciences Lawyer’s Guide to PTA and PTE
Ahmedabad, November 26, 2006 Kiyoshi Kuzuwa Patent Attorney
Globular Protein Made of amino acid chains
Bound antibodies Creative Biolabs provides anti-idiotypic antibody production service detecting FREE antibodies. We have extensive experience in developing.
Induced Pluripotent Stem Cells (iPS)
Stem Cells Peter Paras, Jr.
What You Didn’t Know That You Didn’t Know About Patents
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Patentable Subject Matter in Korea
Presentation transcript:

Patenting Biotechnology in Japan and recent hot issues AIPLA Mid-Winter Meeting January 25, 2012 Ayako Kobayashi TMI Associates

Summary Patenting stem cells Patenting antibodies New Examination Guidelines for applications for Patent Term Extension Regulations for Biosimilars

Patenting stem cells Novelty - Inherent features of the prior art cell How to specify new cells expression profile of surface markers origin morphology preparation method functions (e.g., “differentiating into XXX.”) Do the Inherent expression or functions of the prior art cells destroy the novelty of the claimed cells?

Patenting stem cells Novelty - Inherent features of the prior art cell In many cases, the JPO Examiners do not consider the inherent features of the prior art cell. Rejected Example (JP2007-200588) Claim 1: An isolated adipose-derived stem cell having a marker profile comprising a combination of STRO-01+, CD49d+, and low or undetectable levels of CD106. The Examiner and Appeal Board denied the novelty, citing a reference that failed to mention the expression profile of surface markers when the inventors and the authors of the prior art overlapped.

Patenting stem cells Novelty – Product-by-process claims The technical scope of a product-by-process claim is NOT limited to the product produced by the process recited in the claim. Example Claim: An induced pluripotent stem cell obtained by introducing genes Oct3/4, Klf4, …into a somatic cell. The Examiner denied the novelty of iPS cells, citing a reference of ES cells, because: - the ES cells expressed the same surface markers as iPS cells. - the claimed cells possibly contained cells in which transgene has been spontaneously deleted.

Patenting stem cells Inventive step The requirement for inventive step does not appear to be high. Sometimes an advantageous effect compared to the prior art cells is required.

Patenting stem cells Enablement requirement Very strict. Functional claims are likely to be rejected. The Examiners often require to limit the scope of the invention to the level of the working examples.

Patenting stem cells Enablement requirement Would an enablement rejection be overcome by submitting additional data? It is more likely that the Examiners will take later-submitted data into consideration in situations where they have already formed an impression that the enablement requirements are satisfied for part of the claimed invention, and the later-submitted data is used to furnish the examples necessary to show that the enablement requirements have also been satisfied for the remainder of the claimed invention. When the original specification fails to include any experimental data, it is almost impossible to overcome an enablement rejection by submitting additional data.

Patenting stem cells Public order, etc. Article 32 An invention liable to contravene public order, morality or public health shall not be patented... When an invention includes a step of destroying an embryo, it will be rejected under Article 32. An invention of culturing or differentiating method of an already-established ES cell line would be acceptable.

Patenting stem cells Stem cell-related patent rights To date, there have been no precedents regarding the patentability or infringement of a stem cell-related invention. Thus, the following issues, for example, remain unresolved: Does the inherent feature of the prior art cells really not destroy the novelty of the claimed cells? Would practicing an ES cell-related invention using iPS cells constitute infringement under the Doctrine of Equivalents?

Patenting Antibodies When the antigen is known, it is necessary to specify the new antibody using its special features and show that the antibody produces an advantageous effect compared to the prior art. When the antibody is not sufficiently specified, the Examiner will reject the application due to: lack of inventive step and/or failure to comply with the enablement and support requirements.

Patenting Antibodies How to specify a new antibody CDR sequences – Successful, but the sequences of all six CDRs should be specified >90% homology of CDR sequences – Not successful Substitutions in CDR sequences – Not successful CDR sequences of either Heavy Chain or Light Chain – Not successful Dissociation Constant (Kd) – Not successful Sister clone obtained from the same hybridoma – Not successful Epitope sequences – Successful in many cases

Patenting Antibodies Recent Examples (1) JP4818107 An isolated antibody or its antigen-binding fragment which specifically binds to the epitope consisting of amino acids 86 to 111 set forth in SEQ ID NO:46. JP4799863 A pharmaceutical composition that inhibits cancerous growth of cells comprising an antigen or its antigen binding site, wherein the antigen or its antigen binding site binds to an epitope located within position 200 to 400 of EphB4 (SEQ ID NO:1), and wherein the epitope comprises GSCVV.

Patenting Antibodies Recent Examples (2) JP4818107 A monoclonal antibody or its Fab fragment, capable of binding to mouse VEGF and human VEGF with Kd values within 10 fold of the other, and is capable of inhibiting the binding of VEGF to a VEGF receptor, and recognizes an epitope comprising residues F17, I83 and Q89 of human VEGF.

Patenting Antibodies Recent Examples (3) JP4637480 An isolated antibody consisting of a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region consists of the amino acids set forth in SEQ ID NO:11 that may comprise 3 or less amino acid substitutions; the light chain variable region consists of the amino acids set forth in SEQ ID NO:12 that may comprise 2 or less amino acid substitutions; and the antibody specifically binds to Ang-1 and Ang-2.

Patent Term Extension (“PTE”) More than one PTEs may be granted based on more than one marketing approvals for the same active ingredient in Japan. The JPO had previously rejected applications for a PTE based on the latter of the two marketing approvals in situations where the former approved drug and the latter approved drug contained the same active ingredient, and were directed to the same disease, even though there were differences in dose or formulation between the two drugs. Under the new guidelines, the Examiner will compare the former approval and the latter approval in terms of the features recited in the claims, in addition to the active ingredient and the subject disease. When all such features are in common between the former and the latter approval, an application for a PTE based on the latter approval would be rejected.

Patent Term Extension Examples Claim 1: A painkiller containing compound A. Former Approval: A painkiller in a tablet form containing 5mg of compound A. Latter Approval (i): A painkiller in an injectable form containing 5mg of compound A. Latter Approval (ii): A painkiller in a tablet form containing 10mg of compound A. Under Old and New Guidelines An application for a PTE based on latter approval (i) or (ii) would be rejected.

Patent Term Extension Examples Claim 1: A painkiller in an injectable form containing compound A. Former Approval: A painkiller in a tablet form containing 5mg of compound A. Latter Approval (i) : A painkiller in an injectable form containing 5mg of compound A. Latter Approval (ii) : A painkiller in a tablet form containing 10mg of compound A. Under Old Guidelines Applications for a PTE based on the latter approvals would have been rejected. Under New Guidelines An application for a PTE based on latter approval (i) would not be rejected, while latter approval (ii) would be rejected.

Patent Term Extension Examples Claim 1: A painkiller comprising compound A. Claim 2: A painkiller according to claim 1 which is in a tablet form. Former Approval: A painkiller in an injectable form containing compound A. Latter Approval : A painkiller in a tablet form containing compound A. Only claim 1 would be considered. Under New Guidelines An application for a PTE based on the latter approval would be rejected.

Patent Term Extension Examples Patent 1: A painkiller comprising compound A. Patent 2: A painkiller in a tablet form comprising compound A. Former Approval: A painkiller in an injectable form containing compound A. Latter Approval : A painkiller in a tablet form containing compound A. Under Old Guidelines An application for a PTE based on the latter approval would have been rejected for both patents 1 and 2. Under New Guidelines An application for a PTE based on the latter approval would be rejected for patent 1 but would not be rejected for patent 2.

Biosimilars “Guidelines for the Quality, Safety and Efficacy Assurance of Biosimilars” and “Handling of nonproprietary and brand names of Biosimilars” were issued by the MHLW in March 2009. The English translation made by Pharmaceutical Research and Manufactures of America can be obtained at: http://www.phrma-jp.org/archives/pdf/others/PFSB-ELD%20Notification%20of%20Handling%20of%20names%20of%20follow-on%20biologics_No.%200304007.pdf http://www.phrma-jp.org/archives/pdf/others/PFSB-ELD%20Notification%20of%20Handling%20of%20names%20of%20follow-on%20biologics_No.%200304011.pdf The first Application for the Marketing Approval for Biosimilar (G-CSF) was filed on December 26, 2011.

Ayako Kobayashi TMI Associates ayako_kobayashi@tmi.gr.jp Thank you! Ayako Kobayashi TMI Associates ayako_kobayashi@tmi.gr.jp